Passage Bio Management
Management criteria checks 2/4
Passage Bio's CEO is Will Chou, appointed in Oct 2022, has a tenure of 2.75 years. total yearly compensation is $1.64M, comprised of 39% salary and 61% bonuses, including company stock and options. directly owns 0.013% of the company’s shares, worth $2.54K. The average tenure of the management team and the board of directors is 2 years and 4.3 years respectively.
Key information
Will Chou
Chief executive officer
US$1.6m
Total compensation
| CEO salary percentage | 39.01% |
| CEO tenure | 2.8yrs |
| CEO ownership | 0.01% |
| Management average tenure | 2yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Jan 07
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Sep 24Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Jun 11We're Keeping An Eye On Passage Bio's (NASDAQ:PASG) Cash Burn Rate
Feb 27Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Nov 13We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully
Jun 23Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Nov 13Passage appoints William Chou CEO
Oct 10Passage Bio GAAP EPS of -$0.73 beats by $0.09
Aug 04We're A Little Worried About Passage Bio's (NASDAQ:PASG) Cash Burn Rate
Jun 03Passage Bio: Worth Keeping An Eye On
Apr 11Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?
Dec 15Passage Bio (NASDAQ:PASG) Is In A Good Position To Deliver On Growth Plans
Aug 19We're Hopeful That Passage Bio (NASDAQ:PASG) Will Use Its Cash Wisely
Mar 08Do Institutions Own Passage Bio, Inc. (NASDAQ:PASG) Shares?
Feb 01
Need To Know: Passage Bio, Inc. (NASDAQ:PASG) Insiders Have Been Buying Shares
Dec 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$63m |
| Dec 31 2024 | US$2m | US$638k | -US$65m |
| Sep 30 2024 | n/a | n/a | -US$69m |
| Jun 30 2024 | n/a | n/a | -US$77m |
| Mar 31 2024 | n/a | n/a | -US$84m |
| Dec 31 2023 | US$1m | US$599k | -US$102m |
| Sep 30 2023 | n/a | n/a | -US$112m |
| Jun 30 2023 | n/a | n/a | -US$112m |
| Mar 31 2023 | n/a | n/a | -US$128m |
| Dec 31 2022 | US$1m | US$112k | -US$136m |
Compensation vs Market: Will's total compensation ($USD1.64M) is above average for companies of similar size in the US market ($USD644.39K).
Compensation vs Earnings: Will's compensation has increased whilst the company is unprofitable.
CEO
Will Chou (52 yo)
Dr. William Chou, MD, also known as Will, has been the Chief Executive Officer and Director of Passage Bio, Inc. from October 10, 2022 and serves as its President. Dr. Chou is an accomplished executive wit...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.8yrs | US$1.64m | 0.013% $ 2.5k | |
| Senior VP | 2yrs | US$861.70k | 0.066% $ 13.1k | |
| General Counsel & Company Secretary | 5.8yrs | US$881.92k | 0.092% $ 18.2k | |
| Chief Scientific Officer | 1.5yrs | no data | no data | |
| Chief Business Officer | 1.5yrs | no data | no data | |
| Senior Vice President of Technical Operations | 2yrs | no data | no data | |
| Senior Vice President of Global Regulatory Affairs | 1.4yrs | no data | no data |
Experienced Management: PASG's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.8yrs | US$1.64m | 0.013% $ 2.5k | |
| Independent Director | less than a year | US$104.59k | 0% $ 0 | |
| Independent Chairwoman of the Board | 4.4yrs | US$128.00k | 0% $ 0 | |
| Independent Director | 6.3yrs | US$92.50k | 0.0080% $ 1.6k | |
| Independent Director | 5.4yrs | US$100.20k | 0.030% $ 6.0k | |
| Independent Director | 5.6yrs | US$100.00k | 0% $ 0 | |
| Independent Director | 4.2yrs | US$94.00k | 0% $ 0 | |
| Independent Director | 2yrs | US$80.89k | 0% $ 0 |
Experienced Board: PASG's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/30 00:55 |
| End of Day Share Price | 2025/07/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Passage Bio, Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Whitney Ijem | Canaccord Genuity |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |
| Gbolahan Amusa Benz | Chardan Capital Markets, LLC |